Raymond James & Associates’s Cymabay Therapeutics CBAY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-57,286
| Closed | -$1.35M | – | 4001 |
|
|
2023
Q4 | $1.35M | Buy |
57,286
+17,771
| +45% | +$420K | ﹤0.01% | 2328 |
|
|
2023
Q3 | $589K | Buy |
39,515
+5,050
| +15% | +$75.3K | ﹤0.01% | 2773 |
|
|
2023
Q2 | $377K | Buy |
34,465
+12,296
| +55% | +$135K | ﹤0.01% | 3082 |
|
|
2023
Q1 | $193K | Sell |
22,169
-6,612
| -23% | -$57.7K | ﹤0.01% | 3470 |
|
|
2022
Q4 | $180K | Sell |
28,781
-23,404
| -45% | -$147K | ﹤0.01% | 3461 |
|
|
2022
Q3 | $183K | Sell |
52,185
-36,527
| -41% | -$128K | ﹤0.01% | 3447 |
|
|
2022
Q2 | $262K | Sell |
88,712
-8,892
| -9% | -$26.3K | ﹤0.01% | 3302 |
|
|
2022
Q1 | $304K | Buy |
97,604
+20,337
| +26% | +$63.3K | ﹤0.01% | 3378 |
|
|
2021
Q4 | $261K | Sell |
77,267
-5,791
| -7% | -$19.6K | ﹤0.01% | 3508 |
|
|
2021
Q3 | $303K | Sell |
83,058
-16,507
| -17% | -$60.2K | ﹤0.01% | 3391 |
|
|
2021
Q2 | $434K | Sell |
99,565
-2,111
| -2% | -$9.2K | ﹤0.01% | 3180 |
|
|
2021
Q1 | $462K | Buy |
101,676
+52,242
| +106% | +$237K | ﹤0.01% | 3059 |
|
|
2020
Q4 | $284K | Buy |
49,434
+21,477
| +77% | +$123K | ﹤0.01% | 3131 |
|
|
2020
Q3 | $202K | Buy |
+27,957
| New | +$202K | ﹤0.01% | 3186 |
|
|
2020
Q1 | – | Sell |
-11,059
| Closed | -$22K | – | 3633 |
|
|
2019
Q4 | $22K | Sell |
11,059
-37,531
| -77% | -$74.7K | ﹤0.01% | 3522 |
|
|
2019
Q3 | $249K | Sell |
48,590
-5,703
| -11% | -$29.2K | ﹤0.01% | 3101 |
|
|
2019
Q2 | $389K | Buy |
54,293
+2,780
| +5% | +$19.9K | ﹤0.01% | 2830 |
|
|
2019
Q1 | $684K | Sell |
51,513
-30,692
| -37% | -$408K | ﹤0.01% | 2444 |
|
|
2018
Q4 | $647K | Buy |
82,205
+5,899
| +8% | +$46.4K | ﹤0.01% | 2369 |
|
|
2018
Q3 | $845K | Buy |
76,306
+33,907
| +80% | +$375K | ﹤0.01% | 2356 |
|
|
2018
Q2 | $569K | Buy |
42,399
+169
| +0.4% | +$2.27K | ﹤0.01% | 2586 |
|
|
2018
Q1 | $549K | Sell |
42,230
-10,918
| -21% | -$142K | ﹤0.01% | 2501 |
|
|
2017
Q4 | $489K | Buy |
53,148
+17,848
| +51% | +$164K | ﹤0.01% | 2533 |
|
|
2017
Q3 | $285K | Buy |
+35,300
| New | +$285K | ﹤0.01% | 2813 |
|